SCHEMBL515018

SCHEMBL515018

COC(=O)Nc1ccc(N)cc1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 6/20 0.67
RAB9A P51151 4/20 0.61
MAPT P10636 3/20 0.61
TDP1 Q9NUW8 2/20 0.58
GAA P10253 2/20 0.58
GFER P55789 2/20 0.58
KDM4E B2RXH2 1/20 0.58
GLA P06280 1/20 0.58
THRB P10828 1/20 0.58
BLM P54132 1/20 0.58
CASP6 P55212 1/20 0.58
HPGD P15428 2/20 0.56
PKM P14618 2/20 0.55
LMNA P02545 2/20 0.55
POLB P06746 2/20 0.55
MEN1 O00255 1/20 0.55
APEX1 P27695 1/20 0.55
KMT2A Q03164 1/20 0.55
CYP2C19 P33261 2/20 0.50
PRSS1 P07477 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11134616 0.89 SMN1; SMN2 (0.55) SMN1; SMN2RAB9AMAPTTDP1GAA
SCHEMBL9609808 0.89 SMN1; SMN2 (0.82) SMN1; SMN2RAB9AMAPTGAAGFER
SCHEMBL7251623 0.82 SMN1; SMN2 (0.72) SMN1; SMN2RAB9AMAPTGAAGFER
SCHEMBL515017 0.81 MAPT (0.59) SMN1; SMN2RAB9AMAPTTDP1GAA
SCHEMBL854996 0.80 RAB9A (0.61) SMN1; SMN2RAB9AMAPTTDP1GAA
SCHEMBL514410 0.80 MAPT (0.53) SMN1; SMN2RAB9AMAPTTDP1GAA
SCHEMBL13513998 0.80 RAB9A (0.67) SMN1; SMN2RAB9AMAPTTDP1GAA
SCHEMBL78108 0.80 MAPT (0.53) RAB9AMAPTTDP1GAAGFER
SCHEMBL18814226 0.80 SMN1; SMN2 (1.00) SMN1; SMN2RAB9AMAPTTDP1KDM4E
SCHEMBL17518815 0.80 SMN1; SMN2 (0.69) SMN1; SMN2RAB9AMAPTGAAGFER

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 100 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101287498-B Psma antibody-drug conjugates PSMA DEV COMPANY LLC 2013-03-27 CN claimed
CN-101287498-A PSMA antibody-drug conjugates PSMA DEV COMPANY LLC (US) 2008-10-15 CN claimed
EP-4522618-A1 TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES COMPOUNDS AS HPK1 INHIBITORS Merck Patent GmbH (DE) 2025-03-19 EP disclosed
CN-116348109-B Piperazine derivative, and preparation method and application thereof 浙江海正药业股份有限公司 2025-01-21 CN disclosed
US-20240025922-A1 TETRAHYDROPYRIDO[3,4-d]PYRIMIDINES AS HPK1 INHIBITORS MERCK HEALTHCARE KGAA (DE) 2024-01-25 US disclosed
US-20240025922-A1 TETRAHYDROPYRIDO[3,4-d]PYRIMIDINES AS HPK1 INHIBITORS MERCK HEALTHCARE KGAA (DE) 2024-01-25 US disclosed
US-20240025922-A1 TETRAHYDROPYRIDO[3,4-d]PYRIMIDINES AS HPK1 INHIBITORS MERCK HEALTHCARE KGAA (DE) 2024-01-25 US disclosed
US-20230373972-A1 PIPERAZINE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF ZHEJIANG HISUN PHARMACEUTICAL CO., LTD. (CN) 2023-11-23 US disclosed
US-20230373972-A1 PIPERAZINE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF ZHEJIANG HISUN PHARMACEUTICAL CO., LTD. (CN) 2023-11-23 US disclosed
US-20230373972-A1 PIPERAZINE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF ZHEJIANG HISUN PHARMACEUTICAL CO., LTD. (CN) 2023-11-23 US disclosed
WO-2023220541-A1 TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES COMPOUNDS AS HPK1 INHIBITORS MERCK PATENT GMBH (DE) 2023-11-16 WO disclosed
US-20040053156-A1 Photosensitive resin precursor composition TORAY INDUSTRIES, INC. (JP) 2004-03-18 US disclosed
US-6696112-B2 POSITIVE-TYPE, PHOTOSENSITIVITY; FLAT PANEL DISPLAYS TORAY INDUSTRIES, INC. (JP) 2004-02-24 US disclosed
EP-1388758-A1 Photosensitive heat resistant resin precursor composition TORAY INDUSTRIES, INC. (JP) 2004-02-11 EP disclosed
EP-1296540-A1 DISPLAY TORAY INDUSTRIES, INC. (JP) 2003-03-26 EP disclosed
US-20020162998-A1 Display TORAY INDUSTRIES, INC. (JP) 2002-11-07 US disclosed
EP-0878740-A1 Radiation sensitive polymer composition TORAY INDUSTRIES, INC. (JP) 1998-11-18 EP disclosed
EP-0018939-B1 1:2 METAL COMPLEX DYESTUFFS OF AZOMETHINES, PROCESS FOR THEIR PREPARATION AND PROCESS FOR DYEING AND PRINTING BY USING THESE DYESTUFFS CIBA-GEIGY AG (CH) 1983-10-05 EP disclosed
US-4315854-A Chromium and cobalt complex amino hydroxy azomethine dyes CIBA-GEIGY CORPORATION (US) 1982-02-16 US disclosed
EP-0018939-A1 1:2 Metal complex dyestuffs of azomethines, process for their preparation and process for dyeing and printing by using these dyestuffs CIBA-GEIGY AG (CH) 1980-11-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240025922-A1 TETRAHYDROPYRIDO[3,4-d]PYRIMIDINES AS HPK1 INHIBITORS PDXK, DTYMK, HIPK1 SMN1; SMN2 3927/4885RAB9A 2076/4885MAPT 3283/4885
US-20230373972-A1 PIPERAZINE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF F7, F11, HABP2 SMN1; SMN2 4054/4885RAB9A 3518/4885MAPT 4565/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.